Keywords: Roche, Russian, Antithrombotic, Development, ChemRar, TeaReks
Roche joins forces with ChemRar on developing new antithrombotic drug for Russia
Article | 30 May 2011
Swiss pharmaceutical major Roche (ROG: SIX) and Russian TeaReks company, a subsidiary of ChemRar, Roche's long-standing partner, have signed a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
